Janus Henderson Group PLC Arvinas, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 23,365 shares of ARVN stock, worth $574,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,365

Previous 23,365 -0.0%

Holding current value

$574,545

Previous $621,000 7.41%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $221,705 - $366,185	-9,064 Reduced 27.95%	23,365 $621,000
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $419,097 - $602,611	11,520 Added 55.1%	32,429 $1.34 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $425 - $1,269	-30 Reduced 0.14%	20,909 $860,000
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $58 - $84	3 Added 0.01%	20,939 $411,000
Q2 2023 Aug 14, 2023	SELL	$21.73 - $31.43 $521 - $754	-24 Reduced 0.11%	20,936 $519,000
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $284,224 - $404,978	10,869 Added 107.71%	20,960 $572,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $327,654 - $577,608	10,091 New	10,091 $345,000
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $1,800 - $2,493	-43 Reduced 0.59%	7,291 $325,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $1,764 - $3,637	49 Added 0.67%	7,334 $308,000
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $439,066 - $594,237	7,285 New	7,285 $490,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $237,586 - $347,125	-3,608 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$73.2 - $107.87 $264,105 - $389,194	3,608 New	3,608 $296,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.31B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Arvinas, Inc. Transaction History